TY - JOUR
T1 - Pharmacological characterization of Solanum cernuum Vell.: 31-Norcycloartanones with analgesic and anti-inflammatory properties
AU - Lopes, Luciane C.
AU - de Carvalho, Joao Ernesto
AU - Kakimore, Marise
AU - Vendramini-Costa, Debora B.
AU - Medeiros, Maria A.
AU - Spindola, Humberto M.
AU - Avila-Roman, Javier
AU - Lourenço, Ana Maria Ferreira da Costa
AU - Motilva, Virginia
N1 - SCOPUSID:84901627553
PMID:23925459
WOS:000336394200004
PY - 2014/6
Y1 - 2014/6
N2 - Cycloeucalenone (1) and 24-oxo-31-norcycloartanone (2) obtained from Solanum cernuum Vell. were assayed to explore their pharmacologic roles. Previous studies showed that (2) has selective activity against lung tumor cell line (NCIH460) which expresses high levels of COX-2, suggesting its role in inflammatory process, and also a link between chronic inflammation and cancerassociated process. Dichloromethane crude extract (DCE) significantly reduced writhing and stretching induced by 0.8 % acetic acid at a dose of 100, 300, and 600 mg/kg, po; oral administration of different doses of (1) and (2) also displayed significant analgesic and anti-inflammatory effects in the writhing acetic acid test (p\0.0001). Selected oral doses of both compounds (100 and 50 mg/kg) were assayed in the carrageenan-induced paw edema model. Compound (2) showed significant activity during the early phase (1.5-6 h) and also in the late phase (48 h) (p\0.01). The anti-nociceptive activity observed for the compounds (1) and (2) and DCE was found to be related to the inhibition of different mediators involved in inflammation and nociceptive process. Both compounds decrease COX-2 protein expression, although only compound (2) reached a significant response (p\0.05 vs control). However, in vitro Sirtuin 1 activity and TNF-a production in THP-1 macrophages were not affected.
AB - Cycloeucalenone (1) and 24-oxo-31-norcycloartanone (2) obtained from Solanum cernuum Vell. were assayed to explore their pharmacologic roles. Previous studies showed that (2) has selective activity against lung tumor cell line (NCIH460) which expresses high levels of COX-2, suggesting its role in inflammatory process, and also a link between chronic inflammation and cancerassociated process. Dichloromethane crude extract (DCE) significantly reduced writhing and stretching induced by 0.8 % acetic acid at a dose of 100, 300, and 600 mg/kg, po; oral administration of different doses of (1) and (2) also displayed significant analgesic and anti-inflammatory effects in the writhing acetic acid test (p\0.0001). Selected oral doses of both compounds (100 and 50 mg/kg) were assayed in the carrageenan-induced paw edema model. Compound (2) showed significant activity during the early phase (1.5-6 h) and also in the late phase (48 h) (p\0.01). The anti-nociceptive activity observed for the compounds (1) and (2) and DCE was found to be related to the inhibition of different mediators involved in inflammation and nociceptive process. Both compounds decrease COX-2 protein expression, although only compound (2) reached a significant response (p\0.05 vs control). However, in vitro Sirtuin 1 activity and TNF-a production in THP-1 macrophages were not affected.
KW - 31-Norcycloartanones
KW - Analgesic
KW - Anti-inflammatory
KW - COX-2
KW - Solanum cernuum Vell
U2 - 10.1007/s10787-013-0182-8
DO - 10.1007/s10787-013-0182-8
M3 - Article
C2 - 23925459
SN - 0925-4692
VL - 22
SP - 179
EP - 185
JO - Inflammopharmacology
JF - Inflammopharmacology
IS - 3
ER -